Latest Articles

Publication Date
Emerging Clinical Trials and Future Therapeutic Strategies in Recurrent Endometrial Cancer - OncLive

Emerging Clinical Trials and Future Therapeutic Strategies in Recurrent Endometrial Cancer OncLive

Published: May 14, 2026, 12:06 a.m.
Risks of gynecological and breast cancers in women with endometriosis or adenomyosis: A nationwide cohort study.

Endometriosis has been associated with several risk factors for cancer, and population-based research has shown that women with endometriosis have a higher risk of several types of cancer. The aim …

Published: May 14, 2026, midnight
UM research team identifies novel targeted therapy for endometrial cancer - University of Macau

UM research team identifies novel targeted therapy for endometrial cancer University of Macau

Published: May 13, 2026, 3:13 a.m.
Elevated CENPA Promotes Endometrial Cancer Progression - Docwire News

Elevated CENPA Promotes Endometrial Cancer Progression Docwire News

Published: May 12, 2026, 11:41 p.m.
Sequencing ADCs in Endometrial Cancer - OncLive

Sequencing ADCs in Endometrial Cancer OncLive

Published: May 12, 2026, 1:04 p.m.
Unmet Needs in Endometrial Cancer - OncLive

Unmet Needs in Endometrial Cancer OncLive

Published: May 12, 2026, 12:59 p.m.
Overcoming Financial and Familiarity Barriers in Endometrial Cancer Management - Pharmacy Times

Overcoming Financial and Familiarity Barriers in Endometrial Cancer Management Pharmacy Times

Published: May 11, 2026, 2:03 p.m.
Clinical Realities of Biomarker Utilization in Advanced Endometrial Cancer - Pharmacy Times

Clinical Realities of Biomarker Utilization in Advanced Endometrial Cancer Pharmacy Times

Published: May 11, 2026, 1:35 p.m.
The power of support: One‑to‑one peer support dramatically improves treatment completion among Black endometrial cancer patients, new trial shows - MSN

The power of support: One‑to‑one peer support dramatically improves treatment completion among Black endometrial cancer patients, new trial shows MSN

Published: May 9, 2026, 10:45 p.m.
Arrivent Announces Ind Clearance For Novel Tetravalent Muc16/Napi2b Targeting Adc Arr-002 With Initial Focus In Ovarian And Endometrial Cancers - TradingView

Arrivent Announces Ind Clearance For Novel Tetravalent Muc16/Napi2b Targeting Adc Arr-002 With Initial Focus In Ovarian And Endometrial Cancers TradingView

Published: May 7, 2026, 12:05 p.m.
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!